List of Excipients in Branded Drug NIPENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	NIPENT	pentostatin	0409-0801	HYDROCHLORIC ACID
Hospira Inc	NIPENT	pentostatin	0409-0801	MANNITOL
Hospira Inc	NIPENT	pentostatin	0409-0801	SODIUM HYDROXIDE

Last updated: August 10, 2026

Nipent (pentostatin) is a legacy injectable oncology product with a simple excipient profile: pentostatin and mannitol in a sterile lyophilized powder, reconstituted with Sterile Water for Injection. Its original formulation has limited patent value because composition, manufacturing, and regulatory exclusivity are long expired. Commercial opportunities are concentrated in supply continuity, ready-to-administer presentation, low-volume oncology packaging, hospital preparation efficiency, and reformulation for storage or administration convenience.

Nipent Pentostatin Excipient Strategy and Commercial Opportunities

What is Nipent and how is it formulated?

Nipent is the brand name for pentostatin, a purine nucleoside analog approved for hairy cell leukemia and used in selected T-cell malignancies. The product is supplied as a sterile, preservative-free lyophilized powder in a single-dose vial.

The labeled formulation contains:

Component	Role
Pentostatin	Active pharmaceutical ingredient
Mannitol	Bulking agent and stabilizer for lyophilization
Sterile Water for Injection	Reconstitution vehicle, supplied separately

The 10 mg vial is reconstituted with 5 mL of Sterile Water for Injection to produce a 2 mg/mL solution before further dilution for intravenous administration. The product does not rely on a conventional buffer system or antimicrobial preservative in its marketed lyophilized presentation. [1]

This formulation is technically conservative. Mannitol provides cake structure and contributes to physical stability during freeze-drying. The absence of a complex excipient system reduces formulation and extractables risk but leaves fewer built-in tools for improving solution stability, ready-to-use shelf life, or administration convenience.

What excipients are used in Nipent?

The principal excipient in the labeled Nipent powder is mannitol. Mannitol is widely used in injectable lyophilized products because it forms an acceptable dried cake and has a long history of parenteral use.

The formulation strategy has several implications:

• It minimizes excipient-related immunogenicity and hypersensitivity concerns.
• It avoids preservatives in a product intended for single-dose use.
• It requires aseptic reconstitution at the hospital or infusion center.
• It creates a commercial opening for products that reduce preparation steps.
• It limits the ability to claim a novel excipient-based composition unless new stability or delivery data support the formulation.

Nipent's current label does not indicate the use of polysorbates, citrate, phosphate, histidine, polyethylene glycol, surfactants, or antimicrobial preservatives. The product therefore differs from many modern biologic and complex injectable formulations that require buffering, surfactant protection, or tonicity adjustment.

Why mannitol matters for a pentostatin generic

A generic manufacturer can generally use the same mannitol-based formulation if it can demonstrate pharmaceutical equivalence, bioequivalence where applicable, sterility, stability, and conformity with FDA requirements. Mannitol is commercially attractive because it is inexpensive, available from multiple suppliers, and supported by extensive injectable-product precedent.

The main technical risks are not the identity of mannitol but:

• Residual moisture after lyophilization.
• Reconstitution time.
• Cake collapse or shrinkage.
• Visible and subvisible particles.
• Assay and degradation-product control.
• Container-closure integrity.
• In-use stability after reconstitution and dilution.
• Compatibility with infusion bags and administration sets.

The product's low dose, high potency, and oncology setting make process control more important than excipient novelty.

What formulation patents protect Nipent?

The original Nipent product is unlikely to have meaningful surviving composition or formulation patent protection. Pentostatin was approved in 1991, and any ordinary U.S. patent protection associated with the original drug substance or product would have expired by now, subject to patent-specific prosecution history and patent-term adjustments. [2]

Publicly available FDA product information identifies the marketed dosage form and excipient composition but does not establish an active, commercially blocking patent estate for the legacy formulation. Patent protection should be distinguished from regulatory requirements: an expired patent does not remove the need to satisfy sterile injectable manufacturing, quality, and abbreviated-application standards.

Potentially relevant patent categories include:

Patent category	Likely present-day significance
Pentostatin composition of matter	Expired
Original lyophilized formulation	Expired or commercially weak
Manufacturing process	Potentially relevant only if a later patent exists and remains enforceable
Container-closure system	Usually narrow and design-aroundable
Ready-to-use formulation	Could support new protection if technically non-obvious
New dosing or combination therapy	More likely to create method-of-use value than excipient value
Drug-device presentation	Possible protection for a specific delivery system

A new entrant should not assume that a formulation patent is irrelevant because the active ingredient is old. A later patent covering a specific concentration, stabilizer combination, reconstitution protocol, or container could affect launch timing. The commercial value of such a patent would depend on claim scope, enablement, written description, prosecution history, and whether the claim covers a clinically meaningful presentation.

When did Nipent lose exclusivity?

Pentostatin's core exclusivity has expired. The drug's FDA approval in 1991 places it outside the period of ordinary new chemical entity exclusivity, which is five years for a standard NCE. Any orphan-drug exclusivity associated with the original indication also expired long ago. [2, 3]

Nipent is therefore a mature small-molecule injectable product rather than a protected innovative medicine. Biosimilar exclusivity does not apply because pentostatin is not a biologic under the Public Health Service Act. Competitive entry would proceed through an abbreviated new drug application, a 505(b)(2) application, or a full application depending on the proposed product and reference-product status.

Does Nipent have Orange Book protection?

The FDA Orange Book is the relevant source for listed patents and regulatory exclusivity associated with approved drug products. A legacy product such as Nipent is not expected to have active NCE or orphan exclusivity. Any active patent listing would need to be assessed by product, strength, dosage form, and current Orange Book edition. [2]

The practical conclusion is that the main barrier to competition is likely product development and market economics, not brand exclusivity. A prospective entrant would still need to evaluate any current listed patents, pediatric exclusivity, regulatory exclusivity, and litigation-triggering certifications before filing.

What generic entry risks exist for Nipent?

Nipent's generic entry risk is high from an intellectual-property perspective and moderate from a commercial-development perspective.

The product is a conventional sterile injectable with a single active ingredient and a simple excipient profile. That makes the formulation relatively understandable. The development burden remains significant because injectable oncology products require validated aseptic processing, reliable lyophilization, sterility assurance, particulate control, and stability data.

The main generic entry scenarios are:

Same lyophilized formulation

A competitor could use pentostatin with mannitol in a 10 mg single-dose vial. This approach would minimize formulation differentiation and simplify regulatory comparability. The weakness is limited commercial differentiation.

Improved lyophilized formulation

A new formulation could alter the bulking agent, add a stabilizer, optimize residual moisture, reduce reconstitution time, or improve post-reconstitution stability. A successful formulation may support a 505(b)(2) strategy or a separate patent position, depending on the extent of change and available reference-product data.

Ready-to-use liquid injection

A liquid presentation could remove reconstitution, but pentostatin's chemical and physical stability would need to support the proposed shelf life, storage conditions, container, and in-use period. This is the clearest technical opportunity and the highest formulation-risk option.

Premixed infusion presentation

A pharmacy-ready bag or syringe could reduce preparation labor. The product would need to address dilution compatibility, adsorption, leachables, photostability, microbial risk, and dose flexibility. The commercial case would depend on purchase contracts and hospital pharmacy economics.

What commercial opportunities exist in Nipent excipients?

The strongest opportunities are not premium excipient sales based solely on replacing mannitol. They are formulation-led products that improve the total cost and reliability of administration.

1. Ready-to-reconstitute or ready-to-use products

A product that reduces preparation steps could appeal to oncology pharmacies. Value would come from lower manipulation, shorter pharmacy workflow, reduced reconstitution error risk, and more predictable administration time.

A dual-chamber vial, prefilled diluent system, or pharmacy-ready presentation could be commercially differentiated without changing the active ingredient. The regulatory pathway would depend on the degree of change and whether the presentation remains pharmaceutically equivalent to the reference product.

2. Improved lyophilization performance

A revised excipient system could improve:

• Reconstitution speed.
• Cake appearance and mechanical strength.
• Residual-moisture control.
• Shipping stability.
• Resistance to temperature excursions.
• Shelf life.
• Batch-to-batch manufacturing yield.

Potential excipients include alternative polyols, amino acids, or buffering agents. Each change introduces new compatibility and regulatory work. Mannitol remains difficult to displace unless the replacement produces a measurable manufacturing or clinical-use benefit.

3. Hospital-use packaging

Nipent is administered in specialized oncology settings, where packaging can influence purchasing decisions. A smaller vial, clearer labeling, barcoded unit dose, tamper-evident closure, or integrated diluent can be more commercially relevant than a novel excipient.

Packaging opportunities include:

• Single-vial dose preparation.
• Integrated reconstitution device.
• Low-dead-volume transfer system.
• Light-protective container.
• Unit-dose pharmacy carton.
• Compatible closed-system transfer presentation.

These products may support device or packaging patents, although the claims would need to be narrow enough to withstand design-around efforts.

4. Contract manufacturing and regional supply

The market for pentostatin is specialized. A manufacturer with sterile lyophilization capacity, validated oncology handling, and regulatory experience may capture value through supply reliability rather than brand differentiation.

The principal operational barriers are:

• Small commercial batch sizes.
• Demand variability.
• High cost of sterile manufacturing.
• Need for validated aseptic filling.
• Limited opportunity to amortize specialized equipment.
• Procurement pressure from hospitals and group purchasing organizations.

A regional or multi-market strategy may improve economics if the same formulation and manufacturing process can support approvals in the United States, Europe, Canada, Japan, and selected emerging markets. Local registration requirements, packaging rules, and supply-chain controls remain separate considerations.

How strong is the patent estate for a new Nipent formulation?

A new pentostatin formulation could obtain patent protection, but patent strength would depend on technical differentiation rather than the age of the active ingredient.

The strongest potential claims would be supported by unexpected results, such as:

• Substantially longer liquid stability.
• A marked reduction in reconstitution time.
• Improved impurity control.
• Enhanced resistance to freeze-thaw or temperature stress.
• A defined excipient ratio linked to a measurable performance benefit.
• Improved compatibility with a specific infusion system.
• A clinically meaningful reduction in preparation burden.

Weak claim strategies would include broad claims covering pentostatin with routine injectable excipients without comparative data. Mannitol, trehalose, sucrose, polysorbates, amino acids, and common buffers are well-known pharmaceutical excipients. A patent relying only on their presence may face obviousness challenges.

A robust filing program would normally separate:

1. Composition claims.
2. Concentration and pH claims.
3. Lyophilization-cycle claims.
4. Reconstitution and dilution claims.
5. Container-closure claims.
6. Device claims.
7. Manufacturing-process claims.
8. Method-of-use claims where the formulation produces a defined clinical or operational benefit.

What regulatory pathway applies to a pentostatin competitor?

A conventional generic pentostatin injection would generally be evaluated under the FDA abbreviated pathway if a suitable reference product and product-specific requirements are available. A materially different formulation or delivery system could require a 505(b)(2) application. [4]

Key regulatory issues include:

• Pharmaceutical equivalence.
• Strength and dosage-form equivalence.
• Sterility and endotoxin control.
• Particulate matter.
• Extractables and leachables.
• Stability after reconstitution.
• Dilution compatibility.
• Container-closure integrity.
• Manufacturing consistency.
• Labeling for preparation and administration.

FDA's Inactive Ingredient Database can support excipient precedent analysis, but prior use in another product does not automatically establish acceptability for every concentration, route, or dosage form. [5]

Which companies could challenge Nipent commercially?

The competitive field is likely to include:

• Generic injectable manufacturers with lyophilization capacity.
• Specialty oncology companies.
• Contract development and manufacturing organizations.
• Regional hospital-injectable suppliers.
• Firms pursuing 505(b)(2) reformulations.
• Pharmacy-prepared or outsourced sterile-compounding suppliers.

The most credible competitors are manufacturers already producing sterile oncology injections. A company without lyophilization and aseptic-fill capability would face a higher entry cost and would likely need a contract manufacturing partner.

Nipent also competes indirectly with alternative treatments for hairy cell leukemia and T-cell malignancies. Clinical substitution can limit the addressable market even when generic entry is legally available. Pentostatin's commercial value is therefore linked to treatment-line positioning, physician familiarity, supply continuity, and reimbursement rather than patent exclusivity alone. [6]

What litigation and Paragraph IV risks affect Nipent?

No major current Paragraph IV or settlement structure is established here for the legacy Nipent formulation. Because the core product is old, the principal litigation risk for a new entrant would arise from later patents covering a specific formulation, manufacturing process, device, or use.

A generic applicant would need to assess:

• Current Orange Book patent listings.
• Paragraph IV certification exposure.
• Non-infringement and invalidity positions.
• Manufacturing-process claims.
• Patent-term adjustment and pediatric extensions.
• State-law substitution and procurement requirements.
• Supply agreements that could create practical, rather than legal, barriers.

A reformulated product may avoid an Orange Book dispute if its patent is not listed or if the product does not rely on the patented presentation. That strategy can reduce litigation risk but may also limit the ability to delay a competing ANDA through patent listing.

What is the commercial outlook for Nipent excipient innovation?

The commercial outlook is selective. A basic mannitol-based generic could be technically feasible but may face limited volume and aggressive injectable pricing. A differentiated product has a better opportunity if it delivers a measurable workflow or stability benefit.

The most attractive product concepts are:

Opportunity	Technical value	Commercial attractiveness
Mannitol-based generic lyophilized vial	Low development complexity	Moderate, margin-sensitive
Faster-reconstituting lyophilized vial	Moderate	Moderate to high
Integrated diluent presentation	High workflow value	High if hospital contracts support premium pricing
Ready-to-use liquid	High convenience	High technical risk
Premixed infusion bag	High pharmacy convenience	Moderate to high
Novel excipient-only reformulation	Variable	Low unless supported by unexpected data
Regional contract manufacturing	Supply value	Moderate
Closed-system transfer presentation	Operational and safety value	Moderate to high

Revenue exposure is difficult to quantify from public product information because pentostatin sales are not generally reported as a separately disclosed major product line. The addressable market is constrained by the rarity of the indications, competing therapies, and the product's use in specialist oncology settings.

Key Takeaways

• Nipent contains pentostatin and mannitol in a sterile lyophilized single-dose vial.
• The original formulation and core exclusivity are long expired.
• Biosimilar rules do not apply because pentostatin is a small molecule.
• A conventional generic faces more manufacturing and market-size risk than patent risk.
• Mannitol remains a practical excipient, but it offers little differentiation by itself.
• The strongest commercial opportunities are ready-to-use, integrated diluent, faster-reconstitution, and pharmacy-efficient presentations.
• A new patent estate would need comparative stability, manufacturing, or workflow data to support strong claims.
• Sterile lyophilization capacity and supply reliability are more important barriers than excipient procurement.
• The commercial market is specialized and likely price-sensitive, making hospital workflow value essential for premium positioning.

FAQs About Nipent Excipient and Commercial Strategy

Can mannitol be replaced in a generic pentostatin injection?

Yes. A manufacturer may evaluate alternative bulking agents or stabilizers, but the replacement must support lyophilization, stability, sterility, reconstitution, and regulatory comparability. Mannitol is likely to remain the lowest-risk starting point.

Could a liquid pentostatin formulation receive new patent protection?

Yes, if the liquid formulation demonstrates a non-obvious stability or usability advantage. A generic liquid composition using routine excipients without supporting comparative data would face a weaker patent position.

Is Nipent eligible for a biosimilar application?

No. Pentostatin is a small-molecule drug. A competitor would generally pursue an ANDA, 505(b)(2) application, or full NDA pathway, depending on the formulation and regulatory basis.

What is the most valuable excipient innovation for pentostatin?

The most valuable innovation would likely be an excipient system that enables a stable ready-to-use liquid or materially faster reconstitution. The commercial benefit must exceed the added stability, packaging, and regulatory costs.

Can a hospital pharmacy compound a pentostatin alternative?

Pentostatin is a hazardous oncology drug requiring controlled sterile preparation. Compounding and outsourcing activities are subject to applicable federal, state, USP, and institutional requirements. Compounding is not equivalent to FDA approval and does not provide the same commercial or substitution status as an approved generic.

References

1. Pfizer Inc. (2012). Nipent (pentostatin) for injection: Prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Content and format. FDA.

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

6. National Cancer Institute. (2024). Adult hairy cell leukemia treatment. National Institutes of Health.